International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)-Reference-Cited by-同舟云学术

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Published:2019-04-25 Issue:1 Volume:17 Page:
ISSN:1477-9560
Container-title:Thrombosis Journal
language:en
Short-container-title:Thrombosis J

Author:

Beyer-Westendorf Jan, ,Camm A. John,Fox Keith A. A.,Le Heuzey Jean-Yves,Haas Sylvia,Turpie Alexander G. G.,Virdone Saverio,Kakkar Ajay K.

Funder

Bayer AG

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1186/s12959-019-0195-7.pdf

Reference39 articles.

1. Franken RA, Rosa RF, Santos SC. Atrial fibrillation in the elderly. J Geriatr Cardiol. 2012;9(2):91–100.

2. Ezekowitz MD. Atrial fibrillation: the epidemic of the new millennium. Ann Intern Med. 1999;131(7):537–8.

3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

4. Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry. Thromb Haemost. 2015;113(6):1247–57.

5. Helmert S, Marten S, Mizera H, Reitter A, Sahin K, Tittl L, et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC registry. J Thromb Thrombolysis. 2017;44(2):169–78.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF;Europace;2023-10

2. A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia;PeerJ;2022-09-09

3. A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies;Pharmacology & Therapeutics;2021-02

4. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study;Netherlands Heart Journal;2021-01-07

5. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study;Acta Cardiologica;2021-01-07